

vents were without success. The compd is quite unstable, and readily forms a black polymer. It was further characterized as the ethyl acetal (XIX).

α^5 -Thiopyridoxal Ethyl Acetal (XIX).— α^5 -Thiopyridoxal (XVIII, 50 mg) was suspended in EtOH (5 ml, dry), and 5 drops of Et₂O satd with HCl gas were added. The mixt was allowed to stand at room temp. The reaction was followed by tlc (EtOAc, *R_f* 0.25 starting material, 0.45 ethyl acetal). After standing for 7 days, only traces of starting material were left. The mixt was evapd to 1 ml *in vacuo*, and the product was sep'd by preparative tlc. The material was eluted with EtOAc and evapd to a small vol, and petr ether was added. Crystn yielded 6.8 mg of the ethyl acetal, hygroscopic crystals: mp 120–122° dec, nmr (CDCl₃) (CH₃CH₂) —77 (tr), (2-CH₃) —151, (CH₃CH₂) —218 (m), (5-CH₂) —257 (broad), (α^4 -H, hemiacetal) —405 (split singlet), (C₆-H) —487. *Anal.* (C₁₀H₁₂NSO₂) C, H, S.

Cannizzaro Reaction of Pyridoxal.—Pyridoxal·HCl (50 mmoles, 102 mg), dissolved in 10 ml of satd Ba(OH)₂ soln, was refluxed for 24 hr. Tlc of the reaction mixt indicated only spots due to pyridoxol and pyridoxic acid. (The identities of the products were confirmed by retardation by boric acid and a positive Gibbs test, as described earlier.²⁷) The mixt was then evapd to dryness, and was thoroughly dried *in vacuo*. The dry white powder was acetylated for gas chromatog (2.5 ml of pyridine and 2.5 ml of Ac₂O for 4 hr). Samples of this mixt were injected into a gas chromatograph operating under standard conditions.³³ Two peaks were observed, with retention times of 9.1 min (pyridoxol acetate) and 2.25 min (4-pyridoxic acid lactone acetate). Comparison of the areas under the curves with each other and with standards run separately showed that the total amts of the acetates were 24.9 mmoles for pyridoxol and 15.4 mmoles for 4-pyridoxic acid. The apparent loss of 4-pyridoxic acid during the reaction may be due to decarboxylation and degradation.

A similar mixt was obtained when pyridoxal·HCl (51 mg, 25 mmoles) was dissolved in strong NaOH soln (1 g of NaOH in 2.5 ml of water) and was heated to 110° for 24 hr.

Hydrazine-*d*₄ Experiments. (a) **4-Deoxyypyridoxol- α^2 -*d*₃, α^4 -*d*₃, α^6 -*d* from Pyridoxol.**—Pyridoxol·HCl (251 mg) and hydrazine-*d*₄ (2 ml, anhyd, supplied by Volk Radiochemical Co.) were refluxed for 16 hr, moisture being excluded. After evapn of

excess hydrazine [80° (0.1 mm)], the residue was extd with boiling EtOH (5 ml) for 10 min and cooled, and the hydrazine·2HCl that crystd was removed by filtration. To the filtrate, 1.5 ml of methanolic HCl (11.2% HCl) was added. On chilling, cryst 4-deoxyypyridoxol·HCl pptd. The yield was 178 mg (73%), mp 254° dec. On addn of Et₂O to the mother liquors, a further 40 mg of 4-deoxyypyridoxol could be obtd; but it was contaminated. Recrystn of the main crop from boiling EtOH gave the pure product, mp 271° (lit.¹⁴ mp 273°), migrating as one spot on tlc (50:50 CHCl₃-MeOH; *R_f* 0.75, not retarded by boric acid). The nmr spectrum in 1 *N* D₂SO₄ shows only an α^4 -H₂ peak at —321 cps; α^2 -H₃, α^4 -H₃, and C₆-H appear as small bumps, indicating virtually complete deuteration.

(b) **4-Deoxyypyridoxol- α^2 -*d*₃, α^4 -*d*₃, α^6 -*d* from 4-Deoxyypyridoxol.**—4-Deoxyypyridoxol·HCl (251 mg) and hydrazine-*d*₄ (2.5 ml) were refluxed for 110 hr. The reaction mixt was worked up as in the preceding expt, yielding 139 mg (60%) of deuterated 4-deoxyypyridoxol·HCl. By using an internal standard and integration, it could be established that α^5 protons were not exchanged, but that α^2 -H₃, α^4 -H₃, and α^6 -H protons were exchanged to the extent of 94–95%.

(c).—Collidine (0.40 ml, pure by nmr spectroscopy) was heated with hydrazine-*d*₄ (2.0 ml) at 120° for 120 hr. On cooling, the reaction mixt sep'd into 2 layers, the upper one containing mostly γ -collidine. The nmr spectrum of this layer was exactly the same as that of the starting γ -collidine, indicating no D exchange.

Acknowledgments.—This study was supported in part by research grants (CA-08793 and CA-11047) from the National Cancer Institutes, U. S. Public Health Service. We wish to express our thanks to Drs. Harry B. Wood and Robert E. Engle of the Cancer Chemotherapy National Service Center for making available to us a quantity of α^5 -pyridoxylmethanol·HCl. Dr. B. Paul prep'd compd XII and Mr. N. Angelino compd XIII. We are also indebted to Drs. A. Bloch, M. Hakala, E. Mihich, and F. Rosen of our department for the biological evaluation of some of the compds reported, and to Mr. N. Angelino for the pyridoxal phosphokinase inhibition studies.

(33) W. Korytnyk, G. Fricke, and B. Paul, *Anal. Biochem.*, **17**, 66 (1966).

Antiestrogenic and Antifertility Compounds. 4. 1,1,2-Triarylalkan-1-ols and 1,1,2-Triarylalk-1-enes Containing Basic Ether Groups¹

D. J. COLLINS,* J. J. HOBBS, AND C. W. EMMENS

Department of Veterinary Physiology, University of Sydney, Sydney, New South Wales 2006, Australia

Received November 12, 1970

In an attempt to relate structure to antiestrogenic and antifertility activity, several 1,1,2-triarylalkan-1-ols and 1,1,2-triarylalk-1-enes containing a basic ether group have been synthesized, and their biological activities examined. Assignments of geometric isomerism in the triarylalkenes are made on the basis of umr data.

The discoveries that the compds **3a**,^{2,3} **1**,^{4,5} and **2**⁶ are orally active antifertility agents, and that by sc administration they inhibit simultaneously applied estradiol,^{2,7–9} prompted us to undertake the synthesis

of **3b** and **3c**, which are previously unknown positional isomers of **3a**, and of compds **4**, which are open chain analogs of **1** and **2**. After we began this work, patents^{10,11} appeared describing some compds of the general type **4**, but these included only 2 of those described in this paper.

Chemistry.—Most of the compds were prepared by standard procedures described in the Experimental Section. Attempts to prepare 1-{*p*-[2-(*N,N*-diethyl-

(1) For paper 3, see D. J. Collins and J. J. Hobbs, *Aust. J. Chem.*, **23**, 1605 (1970).

(2) L. J. Lerner, F. J. Holthaus, Jr., and C. R. Thompson, *Endocrinology*, **63**, 295 (1958).

(3) S. J. Segal and W. O. Nelson, *Proc. Soc. Exp. Biol. Med.*, **98**, 431 (1958).

(4) D. Lednicer, J. C. Babcock, S. C. Lyster, J. C. Stucki, and G. W. Duncan, *Chem. Ind. (London)*, 2098 (1961); D. Lednicer, J. C. Babcock, P. E. Marlatt, S. C. Lyster, and G. W. Duncan, *J. Med. Chem.*, **8**, 52 (1965).

(5) G. W. Duncan, J. C. Stucki, S. C. Lyster, and D. Lednicer, *Proc. Soc. Exp. Biol. Med.*, **109**, 163 (1962).

(6) G. W. Duncan, S. C. Lyster, J. J. Clark, and D. Lednicer, *ibid.*, **112**, 439 (1963).


(7) L. E. Barnes and R. K. Meyer, *Fert. Steril.*, **13**, 472 (1962).

(8) C. W. Emmens, R. I. Cox, and L. Martin, *Recent Progr. Hormone Res.*, **18**, 415 (1962).



(9) C. W. Emmens and L. Martin, *J. Reprod. Fert.*, **9**, 269 (1965).

(10) Imperial Chemical Industries Ltd., Belgian Patent 637389 (March 13, 1964); *Chem. Abstr.*, **62**, 10373 (1965).

(11) H. A. DeWald (Parke, Davis and Co.), U. S. Patent 3,288,806 (Nov 29, 1966); *Chem. Abstr.*, **66**, 37765 (1967).



	R ₁	R ₂	R ₃	R ₄
3a	OCH ₂ CH ₂ NEt ₂	H	H	OMe
3b	OCH ₂ CH ₂ NEt ₂	OMe	H	H
3c	H	OMe	H	OCH ₂ CH ₂ NEt ₂
3d	H	OMe	H	OTpy
3e	H	OMe	Me	H
3f	OCH ₂ CH ₂ NEt ₂	OMe	Me	OMe
3g	OCH ₂ CH ₂ NEt ₂	H	Et	OMe
3h	OCH ₂ CH ₂ N	OMe	Et	OMe
3i	OCH ₂ CH ₂ NMe ₂	OMe	Et	OMe
3j	OCH ₂ CH ₂ NEt ₂	OH	Et	OMe
4a	OCH ₂ CH ₂ NEt ₂	OMe	H	H
4b	H	OMe	Me	H
4c	OCH ₂ CH ₂ NEt ₂	OMe	Me	H
4d	OCH ₂ CH ₂ NEt ₂	OMe	Me	OMe
4e	OCH ₂ CH ₂ NEt ₂	H	Et	OMe
4f	OCH ₂ CH ₂ N	OMe	Et	OMe
4g	OCH ₂ CH ₂ NMe ₂	OMe	Et	OMe
4h	OCH ₂ CH ₂ NEt ₂	OH	Et	OMe
4i	OCH ₂ CH ₂ NEt ₂	OMe	Et	OMe
4j	OCH ₂ CH ₂ NEt ₂	OMe	CHMe ₂	OMe
4k	OCH ₂ CH ₂ N	OMe	CHMe ₂	OMe
4l	OCH ₂ CH ₂ NMe ₂	H	Et	H
4m	OCH ₂ CH ₂ NEt ₂	OMe	Et	H
4n	OCH ₂ CH ₂ NEt ₂	H	Et	H
4o	OCH ₂ CH ₂ N	OMe	NO ₂	H
4p	OMe	OMe	Et	OCH ₂ CH ₂ NEt ₂
4q	OMe	H	Et	OCH ₂ CH ₂ NEt ₂



	R	R ₁	R ₂	R ₃
5a	OCH ₂ CH ₂ NEt ₂	6a	H	OMe
5b	OCH ₂ CH ₂ NMe ₂	6b	OMe	H
5c	OCH ₂ CH ₂ N	6c	OMe	Me
		6d	H	Et
		6e	OTpy	Et
		6f	OMe	Me
		6g	OMe	Et
		6h	OMe	CHMe ₂
		6i	H	H
		6j	H	OCH ₂ CH ₂ NEt ₂

amino)ethoxy]phenyl}-1-(*p*-methoxyphenyl)-2-phenylethanol (**3b**) by reaction of the Grignard reagent from *p*-[2-(*N,N*-diethylamino)ethoxy]bromobenzene with 2-phenyl-4'-methoxyacetophenone gave only the dehydration product **4a** upon work-up with NH₄Cl. Extreme ease of dehydration of **3b** compared with **3a** and **3c** is probably due to efficient stabilization of the potential carbonium ion from **3b** by the 1,1-di-*p*-alkoxyphenyl system. The carbinol **3c** was readily obtained by reaction of *p*-MeOC₆H₄MgBr with 2-[*p*-[2-(*N,N*-diethylamino)ethoxy]phenyl]acetophenone (**6j**).

The 1,1,2-triarylethanol listed in Table I were prepared in a similar manner and were dehydrated with either *p*-TsOH or with 20% v/v H₂SO₄ in HOAc to give the 1,1,2-triarylethanes listed in Table II.

It was considered that some of the basic triarylethyl- enes might possibly have been contaminated with the by-product of Grignard coupling. Pure 4,4'-bis[2-(*N,N*-diethylamino)ethoxy]biphenyl was prepared and its nmr spectrum measured: it was not detected in any of the compds prepared from *p*-[2-(*N,N*-diethylamino)ethoxy]phenylmagnesium bromide.

Geometric Isomerism and Nmr Data.—Resolution of geometric isomers was difficult. Pure *trans* isomers of the olefins **4i** and **4f** were obtained, but in no case could the *cis* isomer be isolated pure. Assignments of geometric configuration to pure isomers, and to component peaks in the nmr spectra of *cis-trans* mixtures are tentative, and were made, in part, by analogy with the work of Bedford and Richardson¹² who used nmr chemical shifts to distinguish between *cis*- and *trans*-**4l**, the configurations of which were subsequently established by X-ray crystallography.¹³

The most useful diagnostic resonances in the nmr spectra of **4l** and related triarylethylenes are those of the triplets due to the OCH₂ of the basic ether groups and to the MeO singlets. For direct comparison we have measured the nmr spectrum of samples of *cis*- and *trans*-**4l**. The OCH₂ triplet for *cis*-**4l** shows a downfield shift of $\Delta = 0.17$ ppm with respect to the corresponding triplet of the *trans* isomer. This is consistent with the expectation that an ArO group "trans conjugated" with an aromatic ring in **4** should be deshielded with respect to the corresponding ArO group which is *trans* to the alkyl group in the geometric isomer. However, out of plane rotation of the Ar group might invalidate this assumption. Certainly, this empirical correlation holds for the simpler case of 4,4'-dimethoxy- α,α' -dimethylstilbene (**7**), the *trans* isomer of which shows a downfield shift of 0.11 ppm for the OMe protons relative to the corresponding peak for the *cis* isomer.


Particularly relevant in this respect is the nmr spectrum of **4p**, a positional isomer of **4i** which cannot exist in geometric isomers. The chemical shift difference ($\Delta = 0.13$ ppm) is the same as that observed between the OMe groups of *cis*- and *trans*-**4q**, and between the peaks at δ 3.66 (*cis*-**4i**), and 3.79 (*trans*-**4i**) for the OMe groups which are, respectively, *trans* to an Et or an anisyl group; similarly in **4f** and **4g**.

For the triplet due to the OCH₂ of the basic ether group, the *cis* isomers of **4f**, **g**, **i**, and **l** show a downfield










(12) G. R. Bedford and D. N. Richardson, *Nature (London)*, **212**, 733 (1966).

(13) B. T. Kilbourn, R. H. B. Mais, and P. G. Owston, *Chem. Commun.*, 291 (1968).

TABLE I
 1,1,2-TRIARYLALKAN-1-OLS

No.	Structure				Mp, °C	Mol formula	Anal.
	R ₁	R ₂	R ₃	R ₄			
3c	H	OMe	H	OCH ₂ CH ₂ NEt ₂	97-98	C ₂₇ H ₃₃ NO ₃	C, H, N
3d	H	OMe	H	OTpy	121-122	C ₂₈ H ₂₈ O ₄	C, H
3e	H	OMe	Me	H	101-102	C ₂₂ H ₂₂ O ₂	C, H
3g	OCH ₂ CH ₂ NEt ₂ · citrate	H	Et	OMe	Gum	C ₂₈ H ₃₇ NO ₃	C, H, N
		H	Et	OMe	101-104	C ₃₅ H ₄₅ NO ₁₀	C, H, N
3h	OCH ₂ CH ₂ N 	OMe	Et	OMe	145-147	C ₃₀ H ₃₇ NO ₄	C, H, N
3i isomer "a"	OCH ₂ CH ₂ NMe ₂	OMe	Et	OMe	73-75	C ₂₈ H ₃₅ NO ₄	C, H, N
3i isomer "b"	OCH ₂ CH ₂ NMe ₂	OMe	Et	OMe	114-115	C ₂₈ H ₃₅ NO ₄	C, H, N
3i	Isomer "b" HCl salt				206-207	C ₂₈ H ₃₆ ClNO ₄	C, H, N, Cl
3j	OCH ₂ CH ₂ NEt ₂ · citrate	OH	Et	OMe	99-100	C ₃₅ H ₄₅ NO ₁₁	C, H, N ^a

^a C: calcd, 64.1; found, 63.5.



shift of 0.13–0.17 ppm relative to that for the respective *trans* isomers; in the case of the *i*-Pr-substituted olefins **4j** and **k**, this downfield shift was appreciably smaller (0.08 ppm), apparently reflecting a steric effect.

Ratios of *cis* and *trans* isomers were estimated from peak heights due to appropriate MeO resonances.

Results of Biological Assays.—Randomly bred mice of the QS strain, or randomly bred albino rats re-

motely derived from the Wistar strain were used in all tests. Vaginal smear tests of estrogenic activity were as described by Emmens.¹⁴ Tests of antiestrogenic activity were all against estradiol-3,17 β , simultaneously administered with the test compd but in a separate injection.

(14) C. W. Emmens, *Methods Horm. Res.*, **2A**, 62 (1969).

TABLE II
 1,1,2-TRIARYALK-1-ENES

No.	Structure				Salt	Mp, °C	Mol formula	Anal.
	R ₁	R ₂	R ₃	R ₄				
4a	OCH ₂ CH ₂ NEt ₂	OMe	H	H	Citrate	106–109	C ₃₃ H ₃₉ NO ₉ ·H ₂ O	C, H, N ^a
4b	OMe	H	Me	H		108	C ₂₂ H ₂₀ O	C, H
4c ^b	OCH ₂ CH ₂ NEt ₂	OMe	Me	H	Citrate	106–109	C ₃₄ H ₄₁ NO ₉	
4d ^c (cis:trans, 55:45)	OCH ₂ CH ₂ NEt ₂	OMe	Me	OMe	Citrate	113–114	C ₃₅ H ₄₃ NO ₁₀ ·H ₂ O	C, H, N
4e	OCH ₂ CH ₂ NEt ₂	H	Et	OMe		90–91	C ₂₉ H ₃₅ NO ₂	C, H, N
trans-4f	OCH ₂ CH ₂ -N-pyrrolidyl	OMe	Et	OMe	HCl	216–218 dec	C ₃₀ H ₃₈ ClNO ₃	C, H, N, Cl
4f (cis:trans, 63:37)	OCH ₂ CH ₂ -N-pyrrolidyl	OMe	Et	OMe	HCl	186–191	C ₃₀ H ₃₈ ClNO ₃	C, H, N, Cl
4g (cis:trans, 50:50)	OCH ₂ CH ₂ NMe ₂	OMe	Et	OMe	HCl	158–160	C ₂₈ H ₃₄ ClNO ₃	C, H, N, Cl
4h	OCH ₂ CH ₂ NEt ₂	OH	Et	OMe		159–160	C ₂₉ H ₃₅ NO ₃	C, H, N
trans-4i	OCH ₂ CH ₂ NEt ₂	OMe	Et	OMe	HCl	192–193	C ₃₀ H ₃₈ ClNO ₃	C, H, N, Cl
4i (cis:trans, 62:38)	OCH ₂ CH ₂ NEt ₂	OMe	Et	OMe		Oil	C ₃₀ H ₃₇ NO ₃	C, H, N
4i (cis:trans, 62:38)	OCH ₂ CH ₂ NEt ₂	OMe	Et	OMe	Citrate	109–111	C ₂₈ H ₃₄ NO ₁₀	
4j (cis:trans, 39:61)	OCH ₂ CH ₂ NEt ₂	OMe	CHMe ₂	OMe	HCl	182–183	C ₃₁ H ₄₀ ClNO ₃	C, H, N, Cl
4k (cis:trans, 18:82)	OCH ₂ CH ₂ -N-pyrrolidyl	OMe	CHMe ₂	OMe	HCl	235–236	C ₃₁ H ₃₈ ClNO ₃	C, H, N, Cl

^a Calcd C, 64.8; H, 6.8; N, 2.3. Found: C, 64.0; H, 6.8; N, 2.4.

^b Lit.¹⁰ mp 102–104°. ^c Lit.¹⁰ mp 106–108°.

Tests of antifertility activity were postcoital, as described in detail by Martin, *et al.*¹⁵ Females were allowed to mate, then dosed on days 1–3 after mating or days 4–6 after mating inclusive, day 1 being the day of finding sperm in the vagina or a vaginal plug. Groups of 10 animals were normally used in these tests. Approximate values for the ED₅₀ derived from such tests are presented, the ED₅₀ being defined as the dose which reduces the number of litters produced to 50% of the control values. For injection, peanut oil was used; for oral administration, 25–50% of propylene glycol in H₂O.

No precise limits of error are presented because only the order of activity of a compd was required, but the error ($P = 0.05$) would not usually exceed 50–200% in antifertility tests. However, in vaginal smear tests in the mouse, most of the compds discussed have remarkably low dose-response slopes (see Table IV) whether given orally or sc, so that estimates of estrogenic activity are very imprecise and would be dependent on technique and perhaps strain of animals to a considerable degree. Thus, a compd with an ED₅₀ of, for example, 1 mg, may still elicit some positive responses at 0.025 mg.

The trans isomer of **4i** had no detectable change in effect over a range of 0.2–5.0 mg in the spayed rat, whereas *cis*-**4i** showed a steeper slope and could be assigned an ED₅₀ of 0.20 mg by injection and 0.25 mg orally.

Before the pure trans isomer of **4i** was obtained, a *cis*-trans mixture (about 62% *cis*) was examined quite extensively, and bioassay results are given for this, as well as for the pure trans isomer. Detailed examination shows that **4i** is very brief in estrogenic action, and that conventional tests must tend to provide negative smears if more than one, at the peak of reaction, is taken. However, even under such attempted conditions, 100% of positive responses was not obtainable. Emmens¹⁶ has shown that **4i** and other similar compds produce a refractoriness to estrogenic stimulation, even to their own action, which develops some days after injection and may be related to the point under discussion. Strangely, tests of antiestrogenicity conducted as described above are negative.

Dose-response lines for these compds as antifertility agents are quite normal. Thus, **4i** administered sc to the mouse in daily doses of 4, 8, and 16 µg on days 1–3 after mating resulted in 80, 22, and 10% of pregnancies, and on days 4–6 after mating in 70, 60, and 22% of pregnancies.

By sc administration, the pure trans isomer of **4i** was less estrogenic and more antifertility in action than the *cis*-enriched material (**4i**), however, given orally they showed about the same potency as estrogens (Table III).

These compds were not antiestrogenic when given sc in mice, except for **4a** and **4b** both of which showed weak activity. However, most were highly active as postcoital antifertility agents in the mouse, and where tested, in the rat. Only **4a** failed to show such activity when tested at doses up to 1 mg/day by injection, the rest showed ED₅₀ values of from <0.002 to 0.060 mg/day (days 1–3) or 0.005 to 0.25 mg/day (days 4–6).

There is thus no correlation between antiestrogenic activity (as currently tested) and antifertility activity. With a typical estrogen¹⁷ the daily dose required postcoitally on days 1–3 or 4–6 approximates to the vaginal smear ED₅₀ in the mouse. Clearly, these compds do not follow that rule. In the isomeric pair, *trans*-**4i** and *cis*-**4i**, the trans compd is less estrogenic than the *cis* compd, but more potent as an antifertility agent. Pure *cis*-**4i** was not obtained, but comparison of the *cis*-enriched material with pure *trans*-**4i** shows similar divergence of activity. Thus, by the assay methods used, there appears to be a dissociation of estrogenic and antifertility activities.

Harper and Walpole¹⁸ reported that *cis*-**4i** is estrogenic in rats and mice and has antifertility activities reasonably explicable on that basis, and that *trans*-**4i** is a more potent estrogen in the mouse than its isomer, and also more potent as an antifertility agent. In the rat, however, they found *trans*-**4i** to be strongly antiestrogenic and yet highly potent as an antifertility agent. We do not find this compd to be more potent as an estrogen than its *cis* isomer in either species, although it is more potent as an antifertility agent in both species.

(15) L. Martin, C. W. Emmens, and R. I. Cox, *J. Endocrinol.*, **20**, 299 (1960).

(16) C. W. Emmens, *J. Reprod. Fert.*, in press.

(17) C. W. Emmens, *ibid.*, **9**, 277 (1965).

(18) M. J. K. Harper and A. L. Walpole, *Nature (London)*, **212**, 87 (1966); *J. Endocrinol.*, **37**, 83 (1967).

TABLE III
 BIOLOGICAL ACTIVITIES OF 1,1,2-TRIARYLALK-1-ENES AND 1,1,2-TRIARYLALKAN-1-OLS

Compd	Biological activities ^a												
	Estrogenic ^b				Antiest ^b mouse	Antifertility (daily dose over 3 days)							
	Mouse		Rat			Mouse		Rat					
	sc	oral	sc	oral		Days 1-3		Days 4-6		Days 1-3		Days 4-6	
4a	>1.00	0.90			0.5	>1.000		1.000					
trans-4l ^d	>0.25	0.25	0.2-5.0	0.2-5.0	Na ^c	0.002	0.001	0.005	0.010	0.015	0.015	0.015	0.015
cis-4l ^d	0.20	0.75	0.20	0.25	Na	0.060	0.020	0.100	0.100	0.150	0.150	0.150	0.150
4c	1.00	0.20			Na	0.020		0.250					
4m ^d	<0.10				Na	>0.018		0.018					
4n ^d	0.60				Na	>0.018		0.018					
4i (cis:trans, 62:38)	2.00	0.20	>2.70	>2.70	Na	0.006	<0.005	0.050	0.015	0.030	0.010	0.100	0.030
trans-4i	>2.70	0.30			Na	0.003		0.006					
trans-4f	0.10	0.10			Na	0.003		0.006					
4j (cis:trans, 39:61)	0.10	Ca. 1.00			Na	<0.002		0.006					
4d (cis:trans, 55:45)	1.00	0.30			1.0	0.020		0.100		0.010	0.010	0.050	<0.050
4o ^d	1.00				Na	0.050		0.100					
3a	>1.00		40.0		1.0	1.000		1.000					
3c	>2.70	>2.70			Na	>0.400		>0.400					
3h	0.20	<0.10			Na	0.050		0.200					
3i	1.00	1.00			Na	0.008		0.050					

^a Tested in rodents; ED₅₀ in mg. ^b Vaginal smear assay. ^c Na = not active at doses up to 1 mg. ^d Tested and included for direct comparison, see Acknowledgments.

 TABLE IV
 DOSE-RESPONSE LINES FOR VAGINAL SMEAR TESTS OF 4i
 (CIS:TRANS, 62:38) IN MICE (10 TO 20 ANIMALS PER GROUP)

Test	Dose of 4i (cis:trans, 62:38), mg	Responses, % +ve, to estradiol-3,17β, to injection,		Dose of μg	Response % +ve
		Injection	Gavage		
1	0.5	40	60	0.015	15
	1.0	53	33	0.030	48
	2.0	48	45	0.060	90
	4.0	53	63		
2	0.05	13	40	0.015	18
	0.10	30	35	0.030	38
	0.20	48	50	0.060	93
	0.40	45	58		

Structure-activity correlations, other than the cis and trans examples cited above, are difficult to see. Substitution of OCH₃ for H at R₄ appears to make no difference, 4d vs. 4c. Comparison of 4c with 4a shows that substitution of CH₃ for H at R₃ increases both estrogenic and antifertility potencies; antifertility potency appears to rise throughout the series H, CH₃, C₂H₅, CH(CH₃)₂ at R₃.

Experimental Section¹⁹

Starting Materials.—The *p*-[2-(*N,N*-dialkylamino)ethoxy]-bromobenzenes (5a,b,c) were prep'd as described by Lednicer, *et al.*⁴

The following deoxybenzoin derivatives were prep'd by the std procedures: 2-(*p*-methoxyphenyl)acetophenone (6a), mp 95–96° (lit.²⁰ 96°); demethylation of this with HBr gave 2-(*p*-hydroxyphenyl)acetophenone, mp 137–139° (lit.²¹ 129°, prep'd from the corresponding *p*-amino comp'd); 2-phenyl-4'-methoxyacetophenone (6b), mp 74–75° (lit.²² 74–75°); 2-phenyl-4'-methoxypropylphenone (6c), bp 224–226° (25 mm), mp 53–56° (lit.²³ 53.5–55°); 2-(*p*-methoxyphenyl)butyrophene (6d),

(19) Melting points are uncorrected. Infrared spectra were recorded with a Perkin-Elmer 137 infracord spectrophotometer. Proton resonance spectra were taken in deuteriochloroform (Me₄Si) on a Varian A60 spectrometer; we are indebted to the Department of Chemistry for these measurements. A 0.25-mm layer of silica gel G (Merck) was used for thin-layer chromatography. Light petroleum refers to the fraction of bp 40–60°. Microanalyses were carried out by the Australian Microanalytical Service, Melbourne, Australia.

(20) G. Drefahl, M. Hartmann, and H. Grosspietsch, *Chem. Ber.*, **91**, 755 (1958).

(21) E. Ney, *Ber.*, **21**, 2445 (1888).

(22) J. S. Buck and W. S. Ide, *J. Amer. Chem. Soc.*, **54**, 3012 (1932).

(23) D. Y. Curtin and M. C. Crew, *ibid.*, **77**, 354 (1955).

an oil purified by column chromatog, and shown to be >99% pure by glc (lit.²⁰ mp 38–39°) was prep'd by alkylation of the corresponding acetophenone with EtI in liq NH₃ contg NaNH₂; 2-(*p*-methoxyphenyl)-4'-tetrahydropyranyloxybutyrophene (6e), mp 90–91°, was prep'd as previously described.²⁴ α-Methyldeoxyanisoin (6f), mp 43–45° (lit. 53–57°, 43°²⁶); α-ethyldeoxyanisoin (6g), mp 51–52° (lit.^{26,27} 47–48°); and α-isopropyldeoxyanisoin (6h), mp 56–58° [lit.²⁵ bp 210–214° (0.8 mm)] were obt'd by the method of Dodds, *et al.*²⁵

2-(*p*-Tetrahydropyranyloxyphenyl)acetophenone (6i).—Treatment of 2-(*p*-hydroxyphenyl)acetophenone with dihydropyran in the usual way gave 2-(*p*-tetrahydropyranyloxyphenyl)acetophenone, mp 112–113°. *Anal.* (C₁₉H₂₀O₃) C, H.

2-[2-(*N,N*-Diethylamino)ethoxy]phenyl] acetophenone (6j).—Alkylation of 2-(*p*-hydroxyphenyl)acetophenone with *N*-(2-chloroethyl)diethylamine in EtOH contg NaOEt afforded 2-[2-(*N,N*-diethylamino)ethoxy]phenyl] acetophenone, mp 69–70°. *Anal.* (C₂₀H₂₅NO₂) C, H, N.

4,4'-Bis[2-(*N,N*-diethylamino)ethoxy]biphenyl.—The Grignard reagent was prep'd from *p*-[2-(*N,N*-diethylamino)ethoxy]-bromobenzene (5.4 g) and Mg turnings (0.48 g) in dry THF under N₂. The cooled reagent was added dropwise to a soln of EtBr (2.2 g) in dry Et₂O (10 ml) contg a suspension of anhyd CoCl₂ (0.15 g) at such a rate as to maintain gentle reflux. The mixt was heated under reflux for 1 hr, then satd NH₄Cl (10 ml) was added. Isolation in the usual way afforded an oil (3.6 g) from which a fraction (0.86 g), bp 230–240° (0.8 mm), was isolated and treated with dry HCl in Et₂O to yield, after several crystns from acetone, the **dihydrochloride**: mp 243–245° dec; nmr spectrum, δ 6.87–7.04 (8 H, AA'BB' aromatic), 4.08 (t, 4 H, *J* = 6.5 Hz, 2 × OCH₂CH₂N<), 2.87 (t, 4 H, *J* = 6.5 Hz, 2 × OCH₂CH₂N<), 2.63 (q, 8 H, *J* = 6.5 Hz, 2 × N(CH₂CH₃)₂), 1.07 (t, 12 H, *J* = 6.5 Hz, 2 × N(CH₂CH₃)₂). *Anal.* (C₂₄H₃₈Cl₂N₂O₂) C, H, N, Cl.

Preparation of Carbinols (3).—To a cooled soln of the Grignard reagent from Mg turnings (0.72 g, 0.03 g-atom) and *N*-pyrrolidinoethoxybromobenzene (8.1 g, 0.03 mole) in THF (50 ml) was added a soln of α-ethyldeoxyanisoin (7.1 g, 0.025 mole) in THF (50 ml). The mixt was heated under reflux under N₂ for 10–18 hr. The cooled reaction mixt was treated with satd NH₄Cl soln (30 ml), and the product ext'd with Et₂O–PhH. The org ext was washed, dried, and evap'd to yield an oil which, in some cases, cryst'd on addn of Et₂O. However, with most preps the Et₂O–PhH layer was sep'd into basic and neutral fractions by extn with HCl (2 *N*). The acid soln was either ext'd with CH₂Cl₂ to afford the triarylethanol and/or triarylethylene as its hydrochloride, or made alk and reext'd with Et₂O–PhH, washed, dried,

(24) D. J. Collins and J. J. Hobbs, *Aust. J. Chem.*, **22**, 1557 (1969).

(25) E. C. Dodds, L. Golberg, W. Lawson, and R. Robinson, *Proc. Roy. Soc., Ser. B*, **127**, 140 (1939).

(26) C. W. Shoppee, J. C. Craig, and R. E. Lack, *J. Chem. Soc.*, 1311 (1961).

(27) A. L. Wilds and W. R. Biggerstaff, *J. Amer. Chem. Soc.*, **67**, 789 (1945).

and evapd. The resultant product was crystd as the free base or purified whenever possible, as the citrate salt.

Dehydration of the Carbinols (3).—Dehydration to the triarylethylene was effected by heating for 5 hr under reflux with *p*-TsOH in PhMe, or by treatment with H₂SO₄-AcOH mixt (20% v/v H₂SO₄) for 5 min at room temp. The hydrochloride was prepared by extn from 2 *N* HCl into CH₂Cl₂. If this HCl salt was noncryst, the base was regenerated, chromatogd on basic alumina (Merck, Grade III), then either converted to the citrate, or to the hydrochloride by std procedures.

Nmr Data.—Nmr data are given in the following manner: chem shifts (δ) are in ppm from Me₄Si; multiplicity, s, singlet; d, doublet; t, triplet; q, quartet, with intensities approx 1:3:3:1; m, multiplet. Relative intensities are given in the number of protons, e.g., 3 H denotes a relative intensity of three protons. Coupling consts (*J*) are in hertz. All data are considered significant to ± 1 of the last significant figure.

In no case was the pure *cis* form of the triarylethylene obtained. When the pure *trans* form was available, the nmr spectrum of the *cis* isomer was derived by difference from the spectrum of a mixt of the isomers. If the nmr spectrum of only a *cis-trans* mixt was obtained, peaks were tentatively assigned to each isomer by analogy with chem shifts for other related pairs. Only the peaks which clearly differed from those in the nmr spectrum for the *trans* form are noted for the *cis* isomer.

The *cis:trans* ratio was estd by measurement of the peak height of the upfield OMe singlet for the *cis* isomer against that for the OMe singlet common to both isomers. The downfield OMe peak for the *trans* isomer in some instances overlapped the upper band of the triplet due to OCH₂ of the *trans* isomer.

1-[*p*-[2-(*N,N*-Dimethylamino)ethoxy]phenyl]-1,2-diphenylbut-1-ene (4l).—For *trans*-4l the nmr data were δ 3.94 (t, 2 H, *J* = 6 Hz, OCH₂CH₂N), 2.64 (t, 2 H, *J* = 6 Hz, OCH₂CH₂N<), 2.47 (q, 2 H, *J* = 7 Hz, =CCH₂CH₃), 2.28 (s, 6 H, N(CH₃)₂), 0.92 (t, 3 H, *J* = 7 Hz, =CCH₂CH₃). For *cis*-4l the nmr data were δ 4.11 (t, 2 H, *J* = 6 Hz, OCH₂CH₂N<), 2.79 (t, 2 H, *J* = 6 Hz, OCH₂CH₂N<), 2.51 (q, 2 H, *J* = 7 Hz, =CCH₂CH₃), 2.38 (s, 6 H, N(CH₃)₂), 0.93 (t, 3 H, *J* = 7 Hz, =CCH₂CH₃).

1,2-Bis(*p*-methoxyphenyl)-1-[*p*-[2-(*N,N*-diethylamino)ethoxy]phenyl]but-1-ene (4i).—For *trans*-4i the nmr data were δ 3.90 (t, 2 H, *J* = 6.5 Hz, OCH₂CH₂N<, upfield wing obscured by OCH₃ signal), 3.79 (s, 3 H, OCH₃), 3.73 (s, 3 H, OCH₃), 2.25–2.87 (m, 8 H, overlapping quartets for =CCH₂CH₃, N(CH₂CH₃)₂, and the triplet for OCH₂CH₂N<), 0.79–1.17 (m, 9 H, overlapping triplets for =CCH₂CH₃ and N(CH₂CH₃)₂). For *cis*-4i the nmr data were δ 4.05 (t, 2 H, *J* = 6.5 Hz, OCH₂CH₂N<), 3.73 (s, 3 H, OCH₃), 3.66 (s, 3 H, OCH₃), 2.27–2.97 (m, 8 H overlapping quartets for =CCH₂CH₃ plus N(CH₂CH₃)₂ and the triplets for OCH₂CH₂N<), 0.79–1.19 (m, 9 H, overlapping triplets for =CCH₂CH₃ and N(CH₂CH₃)₂).

A prepn designated 4i was shown to have a *cis:trans* ratio of approximately 62:38.

1-[*p*-[2-(*N,N*-Diethylamino)ethoxy]phenyl]-1,2-bis(*p*-methoxyphenyl)prop-1-ene (4d).—For *trans*-4d the nmr data were δ 3.91 (t, 2 H, *J* = 6 Hz, OCH₂CH₂N<), 3.79, 3.72 (s, 6 H, 2 \times OCH₃), 2.38–2.98 (m, 6 H, overlapping triplet and quartets due to OCH₂CH₂N(CH₂CH₃)₂), 2.09 (s, 3 H, =CCH₃), 1.07, 1.02 (t, 6 H, *J* = 6 Hz, N(CH₂CH₃)₂, signal from *cis:trans* mixture). For *cis*-4d the nmr data were δ , 4.04 (t, 2 H, *J* = 6 Hz, OCH₂CH₂N<), 3.72, 3.67 (s, 6 H, 2 \times OCH₃).

1,2-Bis(*p*-methoxyphenyl)-1-[*p*-[2-(*N*-pyrrolidinoethoxy)-phenyl]but-1-ene (4f).—For *trans*-4f the nmr data were δ 3.99 (t, 2 H, *J* = 6 Hz, OCH₂CH₂N<), 3.81 (s, 3 H, OCH₃), 3.76 (s, 3 H, OCH₃), 2.24–2.96 (8 H, partially resolved triplets and quartet

due to CH₂'s bonded to N of OCH₂CH₂N(CH₂)₄ and =CCH₂CH₃), 1.63–1.92 (m, 4 H, β -CH₂'s of pyrrolidiny), 0.94 (t, 3 H, =CCH₂CH₃). For *cis*-4f the nmr data were δ 4.13 (t, 2 H, *J* = 6 Hz, OCH₂CH₂N<), 3.76 and 3.68 (s, 6 H, 2 \times OCH₃), 2.91 (t, 2 H, *J* = 6 Hz, OCH₂CH₂N<), 2.22–2.78 (m, 6 H overlapping bands due to α -CH₂'s of pyrrolidiny and =CCH₂CH₃).

1,2-Bis(*p*-methoxyphenyl)-1-[*p*-[2-(*N,N*-dimethylamino)-ethoxy]phenyl]but-1-ene (4g).—For *trans*-4g the nmr data were δ 3.95 (t, 2 H, *J* = 6 Hz, OCH₂CH₂N<), 3.80 (s, 3 H, OCH₃), 3.75 (s, 3 H, OCH₃), 2.64 (t, 2 H, *J* = 6 Hz, partially resolved triplet due to OCH₂CH₂N(CH₃)₂), 2.33 (s, 6 H, N(CH₃)₂), 2.44 (q, 2 H, *J* = 7 Hz =CCH₂CH₃), 0.92 (t, 3 H, *J* = 7 Hz, =CCH₂CH₃). For *cis*-4g the nmr data were δ 4.09 (t, 2 H, *J* = 6 Hz, OCH₂CH₂N(CH₃)₂), 3.75 (s, 3 H, OCH₃), 3.68 (s, 3 H, OCH₃), 2.74 (t, 2 H, *J* = 6 Hz, partially resolved triplet due to OCH₂CH₂N(CH₃)₂), 2.29 (s, 6 H, N(CH₃)₂).

1,2-Bis(*p*-methoxyphenyl)-1-[*p*-[2-(*N,N*-diethylamino)ethoxy]phenyl]-3-methylbut-1-ene (4j).—For *trans*-4j the nmr data were δ 3.89 (partially resolved triplet, 2 H, *J* = 6 Hz, OCH₂CH₂N<), overlapped by 3.80 (s, 3 H, OCH₃), 3.74 (s, 3 H, OCH₃), 2.89–3.32 (m, 1 H, CH(CH₃)₂), 2.35–2.89 (m, 6 H, OCH₂CH₂N(CH₂CH₃)₂), 0.73–1.24 (m, 12 H, incompletely resolved doublets and triplets corresponding to CH(CH₃)₂ and N(CH₂CH₃)₂ of the *cis* and *trans* isomers of 4j, resp.) For *cis*-4j the nmr data were δ 4.05 (t, 2 H, *J* = 6 Hz, OCH₂CH₂N<), 3.74, 3.62 (s, 6 H, 2 \times OCH₃).

1,2-Bis(*p*-methoxyphenyl)-1-[*p*-[2-(*N*-pyrrolidinoethoxy)-phenyl]-3-methylbut-1-ene (4k).—For *trans*-4k the nmr data were δ 3.95 (t, 2 H, *J* = 6 Hz, OCH₂CH₂N<), 3.81, 3.74 (s, 6 H, 2 \times OCH₃), 2.37–3.18 (m, 7 H, CH(CH₃)₂ + CH₂'s bonded to N of OCH₂CH₂N(CH₂)₄), 1.60–1.92 (m, 4 H, β -CH₂'s of pyrrolidiny), 0.93 (d, 6 H, CH(CH₃)₂). For *cis*-4k the nmr data were δ 4.03 (t, 2 H, OCH₂CH₂N<), 3.74, 3.64 (s, 6 H, 2 \times OCH₃).

2-[*p*-[2-(*N,N*-Diethylamino)ethoxy]phenyl]-1-(*p*-methoxyphenyl)-1-phenylbut-1-ene (4q).—For *trans*-4q the nmr data were δ 4.00 (t, 2 H, *J* = 6.5 Hz, OCH₂CH₂N<), 3.81 (s, 3 H, OCH₃), 2.21–1.92 (m, 8 H, OCH₂CH₂N(CH₂CH₃)₂ plus =CCH₂CH₃), 0.74–1.30 (m, 9 H, N(CH₂CH₃)₂, =CCH₂CH₃). For *cis*-4q the nmr data were δ 3.68 (s, 3 H, OCH₃).

2-[*p*-[2-(*N,N*-Diethylamino)ethoxy]phenyl]-1,1-bis(*p*-methoxyphenyl)but-1-ene (4p).—The nmr data for this comp were δ 4.00 (t, 2 H, *J* = 6.5 Hz, OCH₂CH₂N<), 3.81, 3.68 (s, 6 H, 2 \times OCH₃), 2.82 (t, 2 H, *J* = 6.5 Hz, OCH₂CH₂N<), 2.63 (q, 4 H, *J* = 6.5 Hz, N(CH₂CH₃)₂), 2.48 (q, 2 H, *J* = 7 Hz, =CCH₂CH₃), 0.76–1.07 (m, 9 H, overlapping triplets for N(CH₂CH₃)₂ and =CCH₂CH₃).

1,2-Bis(*p*-methoxyphenyl)-1-[*p*-[2-(*N,N*-dimethylamino)-ethoxy]phenyl]butan-1-ol (3i).—The nmr data for this comp were δ 3.95 (t, 2 H, *J* = 6 Hz, OCH₂CH₂N<), 3.80 (s, 3 H, OCH₃), 3.72 (s, 3 H, OCH₃), 3.46 (t, 1 H, *J* = 7 Hz, benzylic), 2.64 (t, 2 H, *J* = 6 Hz, OCH₂CH₂N<), 2.29 (s, 6 H, N(CH₃)₂), 1.76 (quintet, 2 H, >CHCH₂CH₃), 0.72 (t, 3 H, *J* = 7 Hz, CH₂CH₃).

Acknowledgments.—This research was supported by grants from the Ford Foundation, and in part, by a grant from Mead Johnson and Co. We are greatly indebted to Imperial Chemical Industries Pty. Ltd., for test samples of *cis*- and *trans*-4l, 4m, and n; to the W.M.S. Merrell Co. for a sample of 3a, and to Parke Davis and Co. for a sample of 4o.